Kondo T
Nihon Rinsho. 2000 Oct;58(10):2055-60.
A guideline regarding the initial therapy for parkinsonian patients is described in this article. The basis for the selection of levodopa or a dopamine(DA) agonist for the initial therapy should depend on the patients' clinical characteristics. Young age, less severe condition of the disease, and absence of dementia are the most important determining factors to initiate DA agonist therapy. In this therapy, the dose should be based on the standard dose of the drug, which is obtained by previous clinical trials. In the case that the initial DA agonist therapy failed, or in the case that levodopa was initially used, the combined use of a DA agonist and levodopa should follow in the earlier period of the therapy.
本文介绍了帕金森病患者初始治疗的指南。左旋多巴或多巴胺（DA）激动剂用于初始治疗的选择依据应取决于患者的临床特征。年轻、病情较轻以及无痴呆是启动DA激动剂治疗的最重要决定因素。在这种治疗中，剂量应基于通过先前临床试验获得的药物标准剂量。如果初始DA激动剂治疗失败，或者最初使用了左旋多巴，则应在治疗早期联合使用DA激动剂和左旋多巴。
